Fiche centre
Riverside Methodist Hospital
Columbus — United States
Essais liés11clinical trials
VilleColumbuslocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03984448
Essais cliniques associés
11| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Biospecimen Collection | Cancer | Phase 2 | NCT06770582 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | RECRUITING |
| Bevacizumab | Cancer | Phase 3 | NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | RECRUITING |
| Recombinant Factor VIIa | Accident vasculaire cérébral | Phase 3 | NCT07227246 | FASTEST Part 2 — Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | RECRUITING |
| Biospecimen Collection | SEP | Phase 2/3 | NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | ACTIVE_NOT_RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | RECRUITING |
| BMS-986368 | Myopathies | Phase 2 | NCT06782490 | MSS — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | RECRUITING |
| Biopsy Procedure | Cancer | Phase 2 | NCT06126276 | Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | RECRUITING |
| Renal Denervation (Symplicity Spyral™) | Hypertension | Non applicable | NCT05198674 | SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN | ACTIVE_NOT_RECRUITING |